The care of the older adult with acute myeloid leukemia or a myelodysplastic syndrome

Annals of Long-Term Care

Volumn 10, Issue 10, 2002, Pages 35-41

  Cripe, Larry D ^a,b   Rutledge, Cheryl K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; THROMBOCYTE CONCENTRATE;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; ERYTHROCYTE CONCENTRATE; GERIATRIC CARE; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LIFE EXPECTANCY; MYELODYSPLASTIC SYNDROME; PROGNOSIS; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 0036819410     PISSN: 15247929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. National Cancer Institute. Surveillance, Epidemiology, and End Results Fast Stats: Acute Myeloid Leukemia. Available at: http://www.seer.cancer.gov/faststats/html/inc_amyl.html. Accessed May 21, 2002.
2. Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994;87(4):743-745.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51(2):89-199.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103(4):620-625.
5. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classifi. cation of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17(12):3835-3849.
6. Bennett JM, Young ML, Andersen JW, et al. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer 1997;80(11 Suppl):2205-2209.
7. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: A review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000;39(1-2):1-18.
8. Baudard M, Marie JP, Cadiou M, et al. Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients. Br J Haematol 1994;86(1):82-91.
9. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079-2088.
10. Heaney ML, Golde DW. Myelodysplasia. New Engl J Med 1999; 340(21):1649-1660.
11. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 2000;24(12):983-992.
12. Taylor PR, Reid MM, Bown N, et al. Acute lymphoblastic leukemia in patients aged 60 years and over: A population-based study of incidence and outcome. Blood 1992;80(7):1813-1817.
13. Stone RM, Mayer RJ. The approach to the elderly patient with acute myeloid leukemia. Hematology Oncology Clinics of North America 1993;7(1):65-79.
14. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86(2):457-462.
15. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998;16(3):872-881.
16. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7(9):1268-1274.
17. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8(2):272-279.
18. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89(1):67-71.
19. Negrin RS, Stein R, Vardiman J, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoletin. Blood 1993;82(3):737-743.
20. Thompson JA, Gilliland DG, Prchal JT, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 2000;95(4):1175-1179.
21. Kurzrock R, Cortes J, Thomas DA, et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001;19(21):4165-4172.
22. Lumadue JA, Ness PM, Current approaches to red blood cell transfusion. Semin Hematol 1996;33(4):277-289.
23. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000;37(2 Suppl 4):3-10.